Ozempic vs Mounjaro: The Complete GLP-1 Showdown (2026)
Ozempic and Mounjaro are the two most prescribed weight loss medications in the world. Combined, they generated over $30 billion in pharmaceutical revenue in 2025. They are prescribed by the same doctors, taken by the same patient populations, and covered (or denied) by the same insurance plans.
But they are fundamentally different drugs with different mechanisms, different clinical profiles, and different optimal patient populations. This analysis breaks down everything — the science, the data, the money, and the compounded alternatives that make the brand price debate irrelevant.
The Head-to-Head Data
| Metric | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug Class | GLP-1 agonist | Dual GLP-1/GIP agonist |
| Receptors Activated | 1 | 2 |
| Mean Weight Loss | 14.9% (STEP 1) | 22.5% (SURMOUNT-1) |
| A1c Reduction (T2D) | -1.5% to -1.8% | -2.0% to -2.4% |
| FDA Approval Year | 2017 (longer track record) | 2022 |
| Injection Frequency | Once weekly | Once weekly |
| Brand Monthly Cost | $935 | $1,059 |
| Compounded Cost (TFX) | $146 | $146 |
| Nausea Rate | 44% | 46% |
| Supply Shortages | Frequent (2023-2025) | Intermittent |
| Weight-Loss Variant | Wegovy (2.4mg) | Zepbound (up to 15mg) |
| Oral Option Available | Yes (Rybelsus) | No |
The Mechanism Gap: Why Two Receptors Beat One
Semaglutide activates the GLP-1 receptor. This triggers appetite suppression through hypothalamic signaling, slows gastric emptying to create earlier satiety, and improves glucose-dependent insulin secretion. It's a proven, powerful mechanism that has helped millions of patients lose weight.
Tirzepatide activates GLP-1 and the GIP receptor. The GIP pathway adds effects that GLP-1 alone cannot produce: enhanced beta-cell function, improved lipid metabolism, direct fat oxidation, and reduced adipose tissue inflammation. This is why tirzepatide outperforms semaglutide in patients with insulin resistance — it addresses metabolic dysfunction through a second pathway that semaglutide cannot reach.
The 22.5% vs 14.9% weight loss gap is not random variation. It's the measurable output of a mechanistically superior drug design in the population studied. Whether that gap applies to your specific metabolism depends on your insulin sensitivity, metabolic profile, and individual receptor expression patterns.
The Trial Data, Unpacked
STEP 1 (Semaglutide/Ozempic class): 1,961 participants with obesity (no diabetes). 68 weeks. Mean body weight reduction of 14.9% at the 2.4mg dose. 32% of participants achieved ≥20% weight loss. Placebo group lost 2.4%.
SURMOUNT-1 (Tirzepatide/Mounjaro class): 2,539 participants with obesity (no diabetes). 72 weeks. Mean body weight reduction of 22.5% at the 15mg dose. 36.2% achieved ≥25% weight loss. Placebo group lost 2.4%.
The critical caveat: These trials used different patient populations, different time frames (68 vs 72 weeks), and different dose optimization protocols. A direct head-to-head trial (SURPASS-2) compared tirzepatide and semaglutide in type 2 diabetes patients and confirmed tirzepatide's superiority — but no head-to-head obesity-only trial has been published.
When Ozempic Wins
When Mounjaro Wins
The Price Problem — And Its Solution
At brand pricing, the Ozempic-vs-Mounjaro decision carries a $124/month financial variable ($935 vs $1,059). This shouldn't influence a clinical decision, but for self-pay patients, it does.
Compounded alternatives eliminate the price variable entirely. Telehealth FX charges $146/month for either molecule — compounded semaglutide or compounded tirzepatide, any dose, flat rate. This transforms the decision from a financial compromise into a pure clinical choice: which molecule matches your metabolic profile?
Real-World vs Trial Results
Trial data represents controlled conditions with motivated, compliant participants. Real-world data is messier — but arguably more relevant to your decision.
Real-world semaglutide data shows average weight loss of 10-12% at 12 months — lower than the 14.9% trial average, primarily due to variable adherence, dose optimization differences, and the fact that real patients eat birthday cake and skip injections during vacations.
Real-world tirzepatide data shows average weight loss of 15-18% at 12 months — still higher than semaglutide's real-world numbers, and the gap persists even with imperfect adherence. The dual-receptor mechanism appears to provide a genuine clinical advantage that survives the transition from controlled trials to real life.
Both medications perform well in the real world. The question isn't whether they work — it's which one works better for your specific metabolism.
Get Matched to the Right Molecule — $146/moOzempic vs Mounjaro FAQ
Which is better for weight loss, Ozempic or Mounjaro?
Trial data shows Mounjaro (tirzepatide) produces greater average weight loss — 22.5% vs 14.9%. However, Ozempic has a longer safety record and individual response varies. The best choice depends on your metabolic profile.
Can I get either without insurance?
Brand prices are $935-$1,059/month without insurance. Compounded alternatives at Telehealth FX cost $146/month flat for either molecule — no insurance required.
What's the actual difference?
Ozempic activates 1 receptor (GLP-1). Mounjaro activates 2 (GLP-1 + GIP). The dual mechanism gives Mounjaro stronger weight loss and insulin sensitivity improvement, particularly for patients with diabetes or insulin resistance.
Can I switch between them?
Yes, with physician guidance. Not simultaneously. Telehealth FX carries both at $146/month, making switching cost-neutral.